Merck gains preclinical compounds designed to exploit DNA repair defects in difficult to treat cancers NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) — Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumors,” said Ranjit S. Bindra, MD, PhD, Modifi Biosciences Co-founder, Harvey and Kate Cushing, Professor of Therapeutic Radiology at Yale School of Medicine, and Scientific Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. “We are honored to have Merck recognize the potential...

Authentic custom avatars, verified voice cloning and guided storyboard scriptwriting facilitate cost-effective, scalable and accessible video training and learningPanopto, the global leader in AI-powered video creation and management solutions, announced its acquisition of Elai, a revolutionary AI text-to-video platform that quickly generates engaging video content for learning with on-screen interactive playback, easy-to-use creator studio tools, and advanced avatar-based learning capabilities, including custom avatars and voice cloning options. With the addition of Elai’s AI video creation solution, the Panopto platform is the only secure video solution capable of supporting the full video learning lifecycle from creation and management to sharing and measuring impact.PITTSBURGH, Oct. 23, 2024 (GLOBE NEWSWIRE)...

EVANSVILLE, Ind. and CHARLOTTE, N.C., Oct. 22, 2024 (GLOBE NEWSWIRE) — Berry Global Group, Inc. (NYSE: BERY) (“Berry”) and Glatfelter Corporation (NYSE: GLT) (“Glatfelter”) announced today that Berry has set a record date of the close of business on November 1, 2024 for the proposed spin-off of its Health, Hygiene and Specialties Global Nonwovens and Films business (“HHNF Business”). The spin-off and merger of Berry’s HHNF Business with Glatfelter are expected to be completed on November 4, 2024, subject to the satisfaction or waiver of the closing conditions for the transaction. As previously announced, in connection with the merger, Glatfelter will effect a reverse stock split and change its name to Magnera Corporation (“Magnera”). Subject to the satisfaction or waiver of the closing conditions, on November 4, 2024, (1) Berry...

Reports Merger Agreement with Bansk Group Approved by Stockholders and Anticipates a Closing Date of October 25, 2024 EAGLE, Idaho, Oct. 22, 2024 (GLOBE NEWSWIRE) — PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, health and wellness company, announced today that at its virtual Special Meeting of Stockholders approximately 80% of its outstanding shares of common stock voted to approve the adoption of the definitive merger agreement (the “Agreement”) pursuant to which Bansk Group will acquire all of the outstanding shares of PetIQ’s common stock for $31.00 per share, in an all-cash transaction valued at approximately $1.5 billion. “On behalf of PetIQ’s Board of Directors, we are excited to announce stockholders’ approval of our proposed transaction with Bansk Group, representing an important milestone...

Acquisition creates a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal degenerations New OPGx-LCA5 Phase 1/2 6-month data demonstrate safety and visual improvement in early onset retinal degeneration Additional clinical data in LCA5 pediatric patients and BEST1 patients is expected in 2H 2025 LYNX-2 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances remains on track for top-line data in Q1 2025 VEGA-3 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75% in presbyopia remains on track for top-line data in H1 2025 Company will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy Projected cash runway extended into 2026 Conference...

Educational Electronics is the first New Orleans-area addition to Sciens’ nationwide expansion. SAN FRANCISCO, Oct. 22, 2024 (GLOBE NEWSWIRE) — Sciens Building Solutions (“Sciens”) today announced it has acquired New Orleans, Louisiana-based Educational Electronics, which introduces the company to this new region. This addition allows Sciens to establish itself in the New Orleans region, as Educational Electronics already provides customers superior service with their stellar reputation, and established area relationships. “Educational Electronics and Sciens have a common goal to deliver the best customer service possible and we know this partnership is going to benefit our existing and future customer base, as well as our valued employees,” said Randy Geier, General Manager of Educational Electronics. “Sciens has a reputation...

Specialty firm adds expertise to National Employee Benefits Practice in steadily growing New England region BOSTON, Oct. 22, 2024 (GLOBE NEWSWIRE) —  Risk Strategies, a leading national specialty insurance brokerage and risk management firm, today announced the acquisition of George W. Blaisdell Insurance, a well-established agency focused on employee benefits based in Hampton Falls, NH. The acquisition further enhances the presence and capabilities of the Risk Strategies Employee Benefits Practice in its New England region. Terms of the deal were not announced. Founded in 1988 by its principal, George W. Blaisdell, the agency has been a successful, specialized provider of employee benefits insurance and related services to clients across the New England region. The agency primarily specializes in designing and delivering group...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ECKOH PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

The dental imaging market is on a remarkable growth trajectory, expanding from $3.37 billion in 2023 to $6.71 billion by 2031, with a robust CAGR of 9%. This surge is driven by advancements in both extraoral (like 3D CBCT systems) and intraoral imaging technologies, catering to vital applications in implantology, orthodontics, and more. Key end users include dental hospitals, clinics, and research institutes, all benefiting from enhanced diagnostic capabilities. Westford, USA, Oct. 22, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that the Global Dental Imaging Market will reach a value of USD 6.71 Billion by 2031, with a CAGR of 9.0% during the forecast period (2024-2031). Dental imaging market is a speedily progressing sector in the healthcare industry, impacted by the rising demand for dental diagnostics and innovations in imaging...

Orthobiologics Market size was valued at USD 6.1 billion in 2022 and is poised to grow from USD 6.43 billion in 2023 to USD 9.87 billion by 2031 Westford, USA, Oct. 22, 2024 (GLOBE NEWSWIRE) — Orthobiologics Market size was valued at USD 6.43 billion in 2023 to USD 9.87 billion by 2031, growing at a CAGR of 5.5% during the forecast period (2024-2031). SkyQuest projects that the Global Orthobiologics Market will reach a value of USD 9.87 Billion by 2031, with a CAGR of 5.5% during the forecast period (2024-2031). Increased incidences of sports injuries and traffic accidents will drive the growth of the orthobiologics market during the forecast period. An increase in cases of spinal illnesses and disorders boosts the growth of the orthobiologics market. Furthermore, the orthobiologics market has been anticipated to be driven by increased...